Clinical trials targeting AP patients with cardiovascular risk factors have indicated that GLP-1 receptor agonists lead to more precise blood glucose control, reduced fluctuations in blood glucose levels, and a steady decrease in glycated hemoglobin levels (95). Here, GLP1R is linked to alkaline phosphatase measurement.